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Abacavir/lamivudine is a combination of two synthetic nucleo-
side analogues which is indicated in antiretroviral combination
therapy for the treatment of human immunodeficiency virus
(HIV) infection in adults and adolescents [1]. A generic product
of abacavir/lamivudine has been developed with lower price
by the Government Pharmaceutical Organization (GPO) to be
an alternative choice of related physicians and patients who
will gain access to the lower price medicines at the same quality
and safety as the reference product. A comparative random-
ized, single dose, two-way crossover, open-label bioequivalence
study of a generic abacavir/lamivudine (600/300-mg) tablets,
alacovir of GPO,Thailand and the reference product, Kivexa of
Glaxo Operation UK, United Kingdom in healthy Thai volun-
teers under fasting conditions was conducted with 7 days wash-
out period between the treatments to compare the rate and
extent of absorption and evaluate the safety of the formula-
tions of abacavir and lamivudine. Blood samples were collected
at predefined time points up to 24 hours. Plasma samples of
subjects were analyzed for abacavir and lamivudine using a
validated LC-MS/MS method. Non-compartmental model was
used for pharmacokinetic analysis and statistical analysis for
twenty-seven subjects who completed both treatments. The
90% parametric confidence intervals for the ln-transformed test/
reference ratios of AUC0-tlast, AUC0-∞ and Cmax were 101.9 (98.37–
105.47), 101.8 (98.42–105.37) and 106.2 (98.53–114.54), respectively
for abacavir and 102.9 (96.24–110.07), 102.4 (96.08–109.20) and
104.5 (96.36–113.37), respectively for lamivudine.These values
were within the acceptable range of 80.00–125.00 [2]. Both for-
mulations were well tolerated. No clinically significant or serious
ADR was observed. The results of statistical analysis showed
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that both formulations were bioequivalent in terms of rate and
extent of absorption.Therefore, this study confirmed that both
formulations can be used interchangeably.
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Fig. 1 Linear plot of mean (±SD) plasma concentrations-time profiles and their semi-logarithmic plot after administration of
test product (T) and reference product (R) of abacavir (A, B) and lamivudine (C, D).
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